- Home
- AHG vs INBX Comparison
AHG vs INBX Comparison
Compare AHG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- INBX
- Stock Information
- Founded
- AHG 2013
- INBX 2010
- Country
- AHG China
- INBX United States
- Employees
- AHG N/A
- INBX N/A
- Industry
- AHG Business Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- INBX Health Care
- Exchange
- AHG Nasdaq
- INBX Nasdaq
- Market Cap
- AHG 245.7M
- INBX 218.9M
- IPO Year
- AHG N/A
- INBX 2020
- Fundamental
- Price
- AHG $1.23
- INBX $13.92
- Analyst Decision
- AHG
- INBX Hold
- Analyst Count
- AHG 0
- INBX 1
- Target Price
- AHG N/A
- INBX N/A
- AVG Volume (30 Days)
- AHG 362.9K
- INBX 81.4K
- Earning Date
- AHG 12-27-2024
- INBX 11-14-2024
- Dividend Yield
- AHG N/A
- INBX N/A
- EPS Growth
- AHG N/A
- INBX N/A
- EPS
- AHG N/A
- INBX 119.38
- Revenue
- AHG $2,414,338.00
- INBX $1,568,000.00
- Revenue This Year
- AHG N/A
- INBX N/A
- Revenue Next Year
- AHG N/A
- INBX N/A
- P/E Ratio
- AHG N/A
- INBX $0.12
- Revenue Growth
- AHG N/A
- INBX 19.24
- 52 Week Low
- AHG $0.60
- INBX $10.80
- 52 Week High
- AHG $2.90
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- AHG 55.14
- INBX 38.33
- Support Level
- AHG $0.82
- INBX $14.53
- Resistance Level
- AHG $1.90
- INBX $15.24
- Average True Range (ATR)
- AHG 0.27
- INBX 0.72
- MACD
- AHG 0.05
- INBX -0.10
- Stochastic Oscillator
- AHG 41.74
- INBX 19.16
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.